Diabetes and obesity – collectively termed diabesity – constitute a rapidly escalating global health crisis, with particularly acute implications in South Asian populations. Unlike classical obesity patterns, South Asians often present a “thin-fat” phenotype – characterized by low body mass index but increased visceral adiposity, insulin resistance, and ectopic fat deposition – leading to earlier and more severe metabolic complications. This review synthesizes current evidence on the intertwined pathophysiology of diabesity, highlighting adipose dysfunction, chronic inflammation, and β-cell exhaustion as central drivers of insulin resistance and cardiometabolic risk. Recent advances in screening – including biomarkers, imaging technologies (dual-energy X-ray absorptiometry, magnetic resonance imaging), and digital monitoring (continuous glucose monitoring, wearables, and artificial intelligence AI analytics) – enable earlier detection and individualized risk stratification. Lifestyle modification remains foundational, supported by behavioral therapy and culturally adapted nutrition and exercise regimens. Pharmacologic innovations such as glucagon-like peptide-1 receptor agonists, dual incretin therapies (e.g., tirzepatide), and sodium-glucose cotransporter-2 inhibitors offer dual benefits in glycemic control and weight loss. For severe cases, bariatric surgery delivers high remission rates, while newer, minimally invasive approaches like electroceuticals, stem cell therapy, and hydrogels show promise in early trials. The integration of AI, telemedicine, and digital therapeutics has revolutionized real-time patient monitoring and engagement. Yet significant disparities persist in access and affordability of care, especially in low- and middle-income countries like India. Future directions must prioritize equitable access, precision medicine through genomics and metabolomics, AI-driven predictive tools, and policy innovations addressing food systems, digital divides, and healthcare funding. A systems-level strategy – combining public health policy, digital innovation, and precision medicine – is vital to combatting the diabesity epidemic in high-risk regions and ensuring scalable, sustainable, and personalized metabolic care.
Samajdar et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: